Key Clinical Publications

Insmed actively publishes and presents clinical data for ARIKACE.

Learn More

Our Mission

Insmed's mission is to improve the lives of patients battling serious orphan lung diseases through novel, targeted inhalation therapies in patient populations with critical unmet needs.

Our Values

The foundation of the Insmed values is our belief that we can make a difference in the lives of patients. The needs of these patients serve as our compass point when setting priorities for the company and weighing difficult decisions. We believe this focus and dedication to patients will provide the foundation of long-term success and shareholder value.

  • Serving patients in need
  • Innovative excellence
  • Personal accountability for company performance
  • Focusing on issues and tasks critical to our company's success
  • Mutual respect, openness and teamwork
  • Working with integrity
  • Fostering diversity of opinions

 

 

*Administered once daily using an optimized eFlow® Electronic Nebulizer (PARI Pharma GmbH).

ARIKACE

(liposomal amikacin
for inhalation)

arikace nebulizer

A differentiated, once-a-day inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.*

Learn More